CN116867911A - 用于胃癌预防和早期发现的生物标志物特征 - Google Patents

用于胃癌预防和早期发现的生物标志物特征 Download PDF

Info

Publication number
CN116867911A
CN116867911A CN202180094230.7A CN202180094230A CN116867911A CN 116867911 A CN116867911 A CN 116867911A CN 202180094230 A CN202180094230 A CN 202180094230A CN 116867911 A CN116867911 A CN 116867911A
Authority
CN
China
Prior art keywords
gastric cancer
biomarkers
patient
lep
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180094230.7A
Other languages
English (en)
Chinese (zh)
Inventor
E·C·图阿蒂
V·米歇尔
D·拉马克
Q·贾伊-贾内托
T·杜什
M·马通多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paris Public Medical Assistance Agency
University Versailles Saint Quentin En Yvelines
Institut Pasteur
Original Assignee
Paris Public Medical Assistance Agency
University Versailles Saint Quentin En Yvelines
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paris Public Medical Assistance Agency, University Versailles Saint Quentin En Yvelines, Institut Pasteur filed Critical Paris Public Medical Assistance Agency
Publication of CN116867911A publication Critical patent/CN116867911A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/20—ICT specially adapted for the handling or processing of medical references relating to practices or guidelines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioethics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202180094230.7A 2020-12-21 2021-12-21 用于胃癌预防和早期发现的生物标志物特征 Pending CN116867911A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20306649.3 2020-12-21
EP20306649 2020-12-21
PCT/EP2021/087155 WO2022136472A1 (en) 2020-12-21 2021-12-21 Biomarkers signature(s) for the prevention and early detection of gastric cancer

Publications (1)

Publication Number Publication Date
CN116867911A true CN116867911A (zh) 2023-10-10

Family

ID=74184396

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180094230.7A Pending CN116867911A (zh) 2020-12-21 2021-12-21 用于胃癌预防和早期发现的生物标志物特征

Country Status (7)

Country Link
US (1) US20240053343A1 (https=)
EP (1) EP4263872A1 (https=)
JP (1) JP2024502253A (https=)
KR (1) KR20230124671A (https=)
CN (1) CN116867911A (https=)
CA (1) CA3202252A1 (https=)
WO (1) WO2022136472A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118483437A (zh) * 2024-07-15 2024-08-13 济南市中心医院 区分普通高血压与难治性高血压的生物标志物及其应用
CN118645252A (zh) * 2024-08-16 2024-09-13 杭州和壹基因科技有限公司 基于深度学习的疾病风险评估方法及系统

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4497005A1 (en) * 2022-03-23 2025-01-29 Serum Detect, Inc. Biomarker signatures indicative of early stages of cancer
CN116500276A (zh) * 2023-04-26 2023-07-28 苏州大学附属儿童医院 一种usf2表达量的检测方法及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101272207B1 (ko) * 2008-02-06 2013-06-07 아지노모토 가부시키가이샤 위암의 평가 방법, 및 위암 평가 장치, 위암 평가 방법, 위암 평가 시스템, 위암 평가 프로그램 및 기록 매체
WO2012167112A2 (en) * 2011-06-01 2012-12-06 Illumina, Inc. Gastric cancer biomarkers
CN104204807B (zh) * 2012-01-20 2016-11-09 阿德莱德研究及创新控股有限公司 用于胃癌的生物标志物及其应用
EP2857520A1 (en) 2013-10-03 2015-04-08 Institut Pasteur Method for in vitro investigating mitochondrial dna levels in a biological sample, kits and uses thereof
CN105572354B (zh) * 2014-10-17 2018-02-02 广州瑞博奥生物科技有限公司 一种检测早期胃癌的抗体芯片试剂盒

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118483437A (zh) * 2024-07-15 2024-08-13 济南市中心医院 区分普通高血压与难治性高血压的生物标志物及其应用
CN118483437B (zh) * 2024-07-15 2024-10-18 济南市中心医院 区分普通高血压与难治性高血压的生物标志物及其应用
CN118645252A (zh) * 2024-08-16 2024-09-13 杭州和壹基因科技有限公司 基于深度学习的疾病风险评估方法及系统
CN118645252B (zh) * 2024-08-16 2025-01-28 杭州和壹基因科技有限公司 基于深度学习的疾病风险评估方法及系统

Also Published As

Publication number Publication date
KR20230124671A (ko) 2023-08-25
US20240053343A1 (en) 2024-02-15
CA3202252A1 (en) 2022-06-30
EP4263872A1 (en) 2023-10-25
WO2022136472A1 (en) 2022-06-30
JP2024502253A (ja) 2024-01-18

Similar Documents

Publication Publication Date Title
US12060617B2 (en) Marker genes for prostate cancer classification
CN116867911A (zh) 用于胃癌预防和早期发现的生物标志物特征
US20180100858A1 (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
Di Meo et al. Searching for prognostic biomarkers for small renal masses in the urinary proteome
WO2019010429A1 (en) METHODS OF DIAGNOSING PANCREATIC CANCER
HK1248316A1 (en) Methods of assessing colorectal health of an individual
KR20080098055A (ko) 암 검출을 위한 소변 유전자 발현 비율
JP2023508701A (ja) 結腸直腸癌又は腺腫を検出するためのバイオマーカー及びその方法
JP2010066225A (ja) 質量分析法を利用した複数癌腫の血液検出のための方法および生物マーカー
CN110229899B (zh) 用于结直肠癌早期诊断或预后预测的血浆标记物组合
He et al. Serum soluble CD14 is a potential prognostic indicator of recurrence of human breast invasive ductal carcinoma with Her2-enriched subtype
US20220326241A1 (en) Proteogenomic methods for diagnosing cancer
EP4384830A1 (en) Method of detecting adenoma
Brégeon et al. MALDI-ToF mass spectrometry for the rapid diagnosis of cancerous lung nodules
US20140256586A1 (en) Methods and compositions for diagnosis of colorectal cancer
Kafle et al. Current state of knowledge on blood and tissue-based biomarkers for opisthorchis viverrini-induced Cholangiocarcinoma: a review of prognostic, predictive, and diagnostic markers
Chen et al. Identification of biomarkers to improve diagnostic sensitivity of sporadic colorectal cancer in patients with low preoperative serum carcinoembryonic antigen by clinical proteomic analysis
JP5429725B1 (ja) 前立腺癌の進行度の評価方法、前立腺癌の検出方法、および検査キット
WO2017219093A1 (en) Screening methods
CN115725730A (zh) 胃癌特异性甲基化标志物及其在胃癌与其他消化道肿瘤的鉴别诊断中的用途
CN113999911A (zh) 用于黑色素瘤免疫治疗药物敏感性预测的产品及用途
Hammoud et al. Diagnosis of esophageal adenocarcinoma by serum proteomic pattern
KR101967100B1 (ko) 대장암의 림프절 전이를 진단하기 위한 miRNA 분별자 및 이를 이용한 대장암에서 림프절 전이 진단 방법
KR20250078101A (ko) 유두암종유사핵모양비침습소포종양의 진단 또는 예후 예측용 바이오마커 및 이를 이용한 갑상선 종양의 치료를 위한 정보제공방법
CN115074436A (zh) 一种肺癌早期诊断标志物在制备肺癌早期诊断试剂中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination